Roger Keresztes

3.6k total citations · 2 hit papers
37 papers, 2.7k citations indexed

About

Roger Keresztes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Roger Keresztes has authored 37 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Roger Keresztes's work include Lung Cancer Treatments and Mutations (11 papers), Inflammatory mediators and NSAID effects (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Roger Keresztes is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Inflammatory mediators and NSAID effects (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Roger Keresztes collaborates with scholars based in United States, Canada and France. Roger Keresztes's co-authors include Shenhong Wu, Xiaolei Zhu, David Chu, Nasser K. Altorki, Richard L. Schilsky, Electra D. Paskett, Susan Halabi, Gideon Steinbach, Robert S. Sandler and Charles L. Loprinzi and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Roger Keresztes

34 papers receiving 2.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer

2003 862 citations Roger Keresztes et al. profile →
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

2008 578 citations David Chu, Roger Keresztes et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger Keresztes United States	19	1.1k	695	655	631	456	37	2.7k
J. Marc Pipas United States	22	1.3k 1.2×	482 0.7×	705 1.1×	464 0.7×	796 1.7×	58	2.4k
Axel Grothey United States	23	2.0k 1.8×	228 0.3×	654 1.0×	1.0k 1.6×	409 0.9×	82	3.3k
Mangesh A. Thorat United Kingdom	19	690 0.6×	189 0.3×	701 1.1×	341 0.5×	559 1.2×	54	1.7k
Mark Wickens United Kingdom	12	2.7k 2.5×	117 0.2×	1.9k 3.0×	541 0.9×	720 1.6×	14	4.6k
Tomomi Kamba Japan	27	1.0k 0.9×	86 0.1×	1.3k 2.0×	1.2k 1.9×	635 1.4×	152	3.3k
K. Syrigos Greece	23	1.1k 1.0×	85 0.1×	388 0.6×	638 1.0×	288 0.6×	73	1.9k
D C Tormey United States	32	2.1k 1.9×	69 0.1×	561 0.9×	718 1.1×	1.1k 2.5×	55	3.6k
Peter Canney United Kingdom	25	1.3k 1.1×	92 0.1×	359 0.5×	472 0.7×	535 1.2×	77	2.6k
Michael B. Boffa Canada	34	188 0.2×	253 0.4×	775 1.2×	510 0.8×	971 2.1×	100	4.2k
Rocío Gónzález‐Conejero Spain	32	120 0.1×	177 0.3×	667 1.0×	367 0.6×	502 1.1×	120	3.0k

Countries citing papers authored by Roger Keresztes

Since Specialization

Citations

This map shows the geographic impact of Roger Keresztes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Keresztes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Keresztes more than expected).

Fields of papers citing papers by Roger Keresztes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Keresztes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Keresztes. The network helps show where Roger Keresztes may publish in the future.

Co-authorship network of co-authors of Roger Keresztes

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Keresztes. A scholar is included among the top collaborators of Roger Keresztes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Keresztes. Roger Keresztes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Majem, Margarita, Roger Keresztes, Yinjun Lou, et al.. (2024). LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671. Immuno-Oncology Technology. 24. 101027–101027.

Ryu, Samuel, Paul T. Finger, Roger Keresztes, et al.. (2023). Unilateral conjunctival Classic Kaposi Sarcoma following a COVID 19 booster. American Journal of Ophthalmology Case Reports. 34. 101986–101986. 2 indexed citations

Khan, Saad A., Zhuoxin Sun, Suzanne E. Dahlberg, et al.. (2021). Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). JTO Clinical and Research Reports. 2(5). 100166–100166. 7 indexed citations

Khan, Saad A., Zijie Sun, Rathi N. Pillai, et al.. (2021). MA01.09 Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). Journal of Thoracic Oncology. 16(3). S131–S132.

Nemesure, Barbara, et al.. (2020). <p>Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy: An Institutional Analysis</p>. Cancer Management and Research. Volume 12. 7165–7171. 3 indexed citations

Keresztes, Roger, et al.. (2020). Severe Immune Thrombocytopenia Induced by a Single Dose of Nivolumab in a Patient with Advanced Non-Small Cell Lung Cancer. Clinics and Practice. 10(2). 1249–1249. 5 indexed citations

Bilfinger, Thomas V., et al.. (2018). Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach. Clinical Lung Cancer. 19(4). 346–351. 58 indexed citations

Zarrabi, Kevin, et al.. (2017). Paraneoplastic Edematous Dermatomyositis: A Rare Syndrome Observed in a Case of Small Cell Lung Cancer. SHILAP Revista de lepidopterología. 7(4). 982–982. 5 indexed citations

Bilfinger, Thomas V., et al.. (2016). Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities. Medical Science Monitor. 22. 2589–2594. 22 indexed citations

10.

Edelman, Martin J., Ming Tan, Mary J. Fidler, et al.. (2014). Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 33(2). 189–194. 27 indexed citations

11.

Ocean, Allyson J., Paul J. Christos, Joseph A. Sparano, et al.. (2014). Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Investigational New Drugs. 32(3). 542–548. 11 indexed citations

12.

Haigentz, Missak, Mimi Kim, Catherine Sarta, et al.. (2012). Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncology. 48(12). 1281–1288. 73 indexed citations

13.

Altorki, Nasser K., Paul J. Christos, Paul C. Lee, et al.. (2011). Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial. Journal of Thoracic Oncology. 6(6). 1121–1127. 20 indexed citations

14.

Chu, David, et al.. (2008). Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients. JAMA. 300(19). 2277–2277. 578 indexed citations breakdown →

15.

Lilenbaum, Rogério, Mark A. Socinski, Nasser K. Altorki, et al.. (2005). PD-076 Phase II randomized trial of irinotecan/docetaxel oririnotecan/gemcitabine with or without celecoxib in 2nd-line treatment of non-small-cell lung cancer. Lung Cancer. 49. S89–S89. 6 indexed citations

16.

Port, Jeffrey L., Robert J. Korst, Paul C. Lee, et al.. (2005). Surgical Resection for Residual N2 Disease After Induction Chemotherapy. The Annals of Thoracic Surgery. 79(5). 1686–1690. 33 indexed citations

17.

Port, Jeffrey L., Michael S. Kent, Robert J. Korst, et al.. (2004). Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. The Annals of Thoracic Surgery. 77(1). 254–259. 76 indexed citations

18.

Ilson, David H., Leonard B. Saltz, Robert T. Heelan, et al.. (1995). A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer. 75(9). 2197–2202. 26 indexed citations

19.

Watanabe, Kentaro, George Lam, Roger Keresztes, & Eric Jaffe. (1992). Lipopolysaccharides decrease angiotensin converting enzyme activity expressed by cultured human endothelial cells. Journal of Cellular Physiology. 150(2). 433–439. 35 indexed citations

20.

Brasitus, Thomas A. & Roger Keresztes. (1984). Protein-lipid interactions in antipodal plasma membranes of rat colonocytes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 773(2). 290–300. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact